Gene therapeutic strategies for neuroprotection: Implications for Parkinson's disease

被引:33
作者
Bowers, WJ
Howard, DF
Federoff, HJ
机构
[1] UNIV ROCHESTER, DEPT NEUROL, DIV MOL MED & GENE THERAPY, ROCHESTER, NY 14642 USA
[2] UNIV ROCHESTER, DEPT MED, ROCHESTER, NY 14642 USA
[3] UNIV ROCHESTER, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA
关键词
D O I
10.1006/exnr.1996.6389
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gene transfer methodologies are being explored as strategies to restore and preserve neuronal function in Parkinson's Disease. This technology represents a new therapeutic modality, holding promise for continuous and localized delivery of neuroprotective molecules. Two primary approaches for gene transfer have emerged: in vivo and ex vivo. Recent advances in the construction and characterization of gene transfer vectors have generated more efficient vehicles to deliver and express candidate therapeutic genes. Direct gene transfer into the CNS can be achieved with replication-deficient viral vectors of several types: adenovirus, adeno-associated virus, and herpes simplex virus. These vector systems are being evaluated in models of Parkinson's disease. Strategies to deliver genes include those that either augment dopamine biosynthesis or attenuate loss of dopaminergic neurons. A discussion of the various approaches is detailed. (C) 1997 Academic Press.
引用
收藏
页码:58 / 68
页数:11
相关论文
共 113 条
[1]   In vivo model of adeno-associated virus vector persistence and rescue [J].
Afione, SA ;
Conrad, CK ;
Kearns, WG ;
Chunduru, S ;
Adams, R ;
Reynolds, TC ;
Guggino, WB ;
Cutting, GR ;
Carter, BJ ;
Flotte, TR .
JOURNAL OF VIROLOGY, 1996, 70 (05) :3235-3241
[2]   TRANSFER OF A FOREIGN GENE INTO THE BRAIN USING ADENOVIRUS VECTORS [J].
AKLI, S ;
CAILLAUD, C ;
VIGNE, E ;
STRATFORDPERRICAUDET, LD ;
POENARU, L ;
PERRICAUDET, M ;
KAHN, A ;
PESCHANSKI, MR .
NATURE GENETICS, 1993, 3 (03) :224-228
[3]   THE PROTOONCOGENE BCL-2 CAN SELECTIVELY RESCUE NEUROTROPHIC FACTOR-DEPENDENT NEURONS FROM APOPTOSIS [J].
ALLSOPP, TE ;
WYATT, S ;
PATERSON, HF ;
DAVIES, AM .
CELL, 1993, 73 (02) :295-307
[4]  
ALTAR CA, 1994, J NEUROCHEM, V63, P1021
[5]   THE NEUROTROPHINS NT-4/5 AND BDNF AUGMENT SEROTONIN, DOPAMINE, AND GABAERGIC SYSTEMS DURING BEHAVIORALLY EFFECTIVE INFUSIONS TO THE SUBSTANTIA-NIGRA [J].
ALTAR, CA ;
BOYLAN, CB ;
FRITSCHE, M ;
JACKSON, C ;
HYMAN, C ;
LINDSAY, RM .
EXPERIMENTAL NEUROLOGY, 1994, 130 (01) :31-40
[6]   GENE-TRANSFER INTO MAMMALIAN CENTRAL-NERVOUS-SYSTEM USING HERPES-VIRUS VECTORS - EXTENDED EXPRESSION OF BACTERIAL LACZ IN NEURONS USING THE NEURON-SPECIFIC ENOLASE PROMOTER [J].
ANDERSEN, JK ;
GARBER, DA ;
MEANEY, CA ;
BREAKEFIELD, XO .
HUMAN GENE THERAPY, 1992, 3 (05) :487-499
[7]  
ANDERSEN JK, 1995, SOMATIC GENE THERAPY, P135
[8]  
Anglade P., 1995, Society for Neuroscience Abstracts, V21, P1250
[9]   NEURAL-TARGETED GENE-THERAPY FOR RODENT AND PRIMATE HEMIPARKINSONISM [J].
ANTON, R ;
KORDOWER, JH ;
MAIDMENT, NT ;
MANASTER, JS ;
KANE, DJ ;
RABIZADEH, S ;
SCHUELLER, SB ;
YANG, J ;
RABIZADEH, S ;
EDWARDS, RH ;
MARKHAM, CH ;
BREDESEN, DE .
EXPERIMENTAL NEUROLOGY, 1994, 127 (02) :207-218
[10]   NEURAL TRANSPLANTATION OF CELLS EXPRESSING THE ANTI-APOPTOTIC GENE BCL-2 [J].
ANTON, R ;
KORDOWER, JH ;
KANE, DJ ;
MARKHAM, CH ;
BREDESEN, DE .
CELL TRANSPLANTATION, 1995, 4 (01) :49-54